



RADAHAIM

Organoids for Drug Development

High
Precision
Data

Global
Regulatory
Alignment


Global
Market
Access

MISSION


- Replace Animal Testing with Organoid
- Quantitative, Reproducible, Regulatory-Ready Data
- Advance Precision Medicine with Human Model
- Set the Standard for Organoid Testing
- Screen Gene Therapy Off-target Effects Using Organoids

OUR PLATFORM & SCIENTIFIC VALIDATION

Standardization & Scalable Organoids (Liver)




Bright Field Image



Marker Expression

Liver Biomarkers & Functional Tests




Comparable or Higher Expression of Key Liver Functional Markers

SERVICES


Drug Efficacy Assessment Platform

- Non-animal preclinical evaluation platform
- Human organoid-based MoA analysis
- FFPE block to organoid microarray workflow
- Spatial transcriptomics & single-cell analysis
- Whole-mount IF and H&E-based histology readout


Spatial Transcriptomics & Single-Cell Analysis



Whole-Mount Immunofluorescence



H & E Staining





SERVICES

DILI Assessment Platform


- Human liver organoid-based non-animal DILI evaluation
- Dose-dependent hepatotoxicity profiling across Cmax ranges
- Cell viability analysis for functional toxicity assessment
- ALT activity measurement as a liver injury biomarker
- Differentiation of Most-DILI and No-DILI compounds

Drug Induced Liver Injury iPSC-derived Toxicity Model



INNOVATIONS


4 Core Technologies for Standardizing and Mass Producing Organoids



BUSINESS MODELS



GLOBAL NETWORKS



10th floor, 123 Unjung-ro, Bundang-gu, Sungnam-Si, Gyeonggi-do, 13461, Republic of Korea
 T. +82-10-2056-5829 E. info@radahaim.com
 www.radahaim.com

Organoids for Drug Development
RADAHAIM

